The effect of Replens(R) on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry

Laak, J.A.W.M. van der; Bie, Liangyu; Leeuw, H. de; Wilde, P.C.M. de; Hanselaar, A. G. J. M.

doi:10.1136/jcp.55.6.446

Cited by 101 publications

(52 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given the equivalent effect on symptoms, use of the lower dose may be prudent. Alternatively, the effect of the higher dose on the thinness of the vaginal epithelium may be associated with greater effectiveness, similar to the difference between symptom improvement with topical estrogens, which reverse the cytologic changes of vaginal atrophy, and with Replens, which does not [8].…”

Section: Discussionmentioning

confidence: 99%

Topical Testosterone for Breast Cancer Patients with Vaginal Atrophy Related to Aromatase Inhibitors: A Phase I/II Study

et al. 2011

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Evaluate early data regarding the impact of daily vaginal testosterone on estradiol and testosterone levels in breast cancer patients receiving treatment with aromatase inhibitors.2. Explain the potential clinical benefits of vaginal testosterone therapy to treat vaginal atrophy in women with breast cancer receiving long-term aromatase inhibitor therapy.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. ABSTRACT Breast CancerThe

show abstract

Section: Discussionmentioning

confidence: 99%

Topical Testosterone for Breast Cancer Patients with Vaginal Atrophy Related to Aromatase Inhibitors: A Phase I/II Study

et al. 2011

View full text Add to dashboard Cite

show abstract

“…However, a Cochrane Review found intravaginal estrogen preparations to be the most effective means to alleviate the symptoms of vulvovaginal atrophy [45]. While some women have symptoms of vaginal dryness ameliorated with regular use of Replens, it has not been shown to improve the maturation index of the vaginal lining [46], or reduce vaginal pH [47]. The effect that Replens has on the incidence of urinary tract infections has not been formally studied.…”

Section: Management Of Urogenital Symptoms In the Non-breast Cancer Pmentioning

confidence: 99%

Should Urogenital Atrophy in Breast Cancer Survivors Be Treated with Topical Estrogens?

et al. 2008

View full text Add to dashboard Cite

Disclosure:The article discusses Replens (Wellspring Pharmaceutical) as a vaginal lubricant/moisturizer and Estring (Pfizer) and Vagifem (Novo Nordisk) as topical estrogen replacements. W.W. has received an honorarium from Wyeth and Berlex as a guest speaker at CME events. No other potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article. LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Describe the urogenital consequences of antiestrogen treatment among women with a prior diagnosis of breast cancer and the effects that these side effects have on quality of life and medication compliance.2. Advise on the standard treatment of urogenital atrophy, including alternatives to topical estrogen replacement, in the non-breast cancer and breast cancer populations.3. Evaluate the evidence for the current recommendations of estrogen replacement therapy among women with a prior diagnosis of breast cancer.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACTBreast cancer survivors represent a unique patient population with a high prevalence of menopausal symptoms. Given the improved longevity of cancer patients, the consequences of menopause have become an increasingly important and challenging management issue. To date, considerable attention has been paid to the management of menopausal vasomotor symptoms and bone health among breast cancer patients. As a result, numerous nonhormonal treatment options have been developed for the management of these issues. The treatment of urogenital symptoms among this population is poorly understood and relatively understudied. Although systemic or topical estrogen replacement is the most effective method for treating hypoestrogenemic urogenital symptoms, women with a prior diagnosis of breast cancer are cautioned from taking exogenous estrogens in order to avoid a potential contribution to recurrent breast cancer risk. This review focuses on the urogenital consequences of estrogen deprivation therapy in breast cancer patients and provides practitioners with a simple guide of current and future strategies for managing these symptoms. The Oncologist 2008;13:222-231

show abstract

“…E-mail: Abbaspoorzahra7@Yahoo.com. from a combination of atrophic changes in the estrogen dependent cells that line the vagina and a reduction in the secretion of cervical mucus which circulates in the vaginal lumen (vander Laak et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Effect of hyaluronic acid and vitamin E vaginal tablets on atrophic vaginitis: A randomized controlled trial

Ziagham¹,

Abbaspoor²,

Abbaspour³

2012

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

The effect of Replens(R) on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry

Abstract: Replens did have an effect on vaginal morphology. The automated procedure may be useful for the assessment of maturation in vaginal smears and is more sensitive to small (subvisual) changes.

Cited by 101 publications

References 6 publications

Topical Testosterone for Breast Cancer Patients with Vaginal Atrophy Related to Aromatase Inhibitors: A Phase I/II Study

Topical Testosterone for Breast Cancer Patients with Vaginal Atrophy Related to Aromatase Inhibitors: A Phase I/II Study

Should Urogenital Atrophy in Breast Cancer Survivors Be Treated with Topical Estrogens?

Effect of hyaluronic acid and vitamin E vaginal tablets on atrophic vaginitis: A randomized controlled trial

Contact Info

Product

Resources

About